• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exposure to Anti-TNF Medications Does Not Increase the Risk of Cardiac Arrhythmia in Inflammatory Bowel Disease: A Population-Based Cohort Study.

作者信息

Larsen L, Olsen K D, Christensen H S, Allin K H, Jess T

机构信息

Department of Clinical Medicine, Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Aalborg University, Copenhagen, Denmark.

Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.

出版信息

Gastro Hep Adv. 2023 Jan 31;2(4):478-479. doi: 10.1016/j.gastha.2023.01.019. eCollection 2023.

DOI:10.1016/j.gastha.2023.01.019
PMID:39132039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11308764/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f639/11308764/8aacda3c7b98/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f639/11308764/8aacda3c7b98/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f639/11308764/8aacda3c7b98/gr1.jpg

相似文献

1
Exposure to Anti-TNF Medications Does Not Increase the Risk of Cardiac Arrhythmia in Inflammatory Bowel Disease: A Population-Based Cohort Study.暴露于抗TNF药物不会增加炎症性肠病患者发生心律失常的风险：一项基于人群的队列研究。
Gastro Hep Adv. 2023 Jan 31;2(4):478-479. doi: 10.1016/j.gastha.2023.01.019. eCollection 2023.
2
Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.抗TNF药物对炎症性肠病患者术后结局的影响：单机构经验
J Gastrointest Surg. 2016 Sep;20(9):1636-42. doi: 10.1007/s11605-016-3194-z. Epub 2016 Jul 12.
3
Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.炎症性肠病中医疗疗法导致术后感染并发症的风险。
Cochrane Database Syst Rev. 2020 Oct 24;10(10):CD013256. doi: 10.1002/14651858.CD013256.pub2.
4
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.阴性筛查不能排除接受抗TNF治疗的炎症性肠病患者患结核病的风险：GETAID队列的描述性研究。
J Crohns Colitis. 2016 Oct;10(10):1179-85. doi: 10.1093/ecco-jcc/jjw129. Epub 2016 Jul 11.
5
Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: a nationwide cohort study.父亲使用治疗炎症性肠病的药物与子女医院诊断感染风险的关系：一项全国性队列研究。
Aliment Pharmacol Ther. 2022 Sep;56(5):823-830. doi: 10.1111/apt.17113. Epub 2022 Jun 30.
6
Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.硫嘌呤和抗 TNF 治疗在炎症性肠病相关淋巴瘤中的作用。
Am J Gastroenterol. 2011 Dec;106(12):2146-53. doi: 10.1038/ajg.2011.283. Epub 2011 Oct 25.
7
Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.硫唑嘌呤和肿瘤坏死因子拮抗剂对炎症性肠病患者原发性硬化性胆管炎结局的影响。
Aliment Pharmacol Ther. 2022 Sep;56(5):857-868. doi: 10.1111/apt.17123. Epub 2022 Jul 4.
8
Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications.免疫抑制药物治疗的炎症性肠病患者中基底细胞癌的反复发作。
Am J Gastroenterol. 2020 Aug;115(8):1246-1252. doi: 10.14309/ajg.0000000000000679.
9
Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.抗肿瘤坏死因子治疗小儿炎症性肠病的严重感染或淋巴瘤风险：系统评价。
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51; quiz e88-9. doi: 10.1016/j.cgh.2014.01.021. Epub 2014 Jan 22.
10
The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.抗 TNF 药物治疗的炎症性肠病患者的带状疱疹严重程度。
Inflamm Bowel Dis. 2018 May 18;24(6):1274-1279. doi: 10.1093/ibd/izx115.

引用本文的文献

1
Multi-faceted potential of sophoridine compound's anti-arrhythmic and antioxidant effects through ROS/CaMKII pathway.槐定碱化合物通过ROS/CaMKII途径产生的抗心律失常和抗氧化作用的多方面潜力。
Heliyon. 2024 Sep 6;10(18):e37542. doi: 10.1016/j.heliyon.2024.e37542. eCollection 2024 Sep 30.

本文引用的文献

1
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.《欧洲溃疡性结肠炎诊断与管理循证共识（第三版）。第二部分：当前管理》
J Crohns Colitis. 2017 Jul 1;11(7):769-784. doi: 10.1093/ecco-jcc/jjx009.
2
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.3 欧盟克罗恩病诊断与管理循证共识 2016：第 1 部分：诊断与医学管理。
J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22.
3
Adverse effects of biologics used for treating IBD.
用于治疗炎症性肠病的生物制剂的不良反应。
Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):167-82. doi: 10.1016/j.bpg.2010.01.002.
4
Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis.英夫利昔单抗急性输注期间的心律失常风险：一项针对慢性关节炎患者的前瞻性、单盲、安慰剂对照、交叉研究。
J Rheumatol. 2008 Oct;35(10):1958-65. Epub 2008 Aug 15.
5
Inflammatory bowel disease: clinical aspects and established and evolving therapies.炎症性肠病：临床特征及已确立和不断发展的治疗方法
Lancet. 2007 May 12;369(9573):1641-57. doi: 10.1016/S0140-6736(07)60751-X.
6
Transient type III atrioventricular block after infliximab infusion in a fistulizing perianal Crohn's disease patient.
Am J Gastroenterol. 2007 Jan;102(1):217-9.
7
A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab.对肿瘤坏死因子α阻滞剂依那西普、英夫利昔单抗和阿达木单抗副作用的全面综述与评估。
J Dermatolog Treat. 2004 Sep;15(5):280-94. doi: 10.1080/09546630410017275.
8
Symptomatic sinus bradycardia with infliximab.
Indian J Gastroenterol. 2004 May-Jun;23(3):118-9.